AstraZeneca Stock Price, News & Analysis (LON:AZN)

GBX 5,043 62.50 (1.25 %)
(As of 01/21/2018 01:33 AM ET)
Previous CloseGBX 5,043
Today's RangeGBX 4,984.50 - GBX 5,054
52-Week RangeGBX 4,136.50 - GBX 5,520
Volume3.02 million shs
Average Volume1.61 million shs
Market Capitalization£63.86 billion
P/E Ratio2,508.96
Dividend YieldN/A
BetaN/A

About AstraZeneca (LON:AZN)

AstraZeneca logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolLON:AZN
CUSIPN/A
Phone+44-20-73045000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio2508.9552238806
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX 2.01
Net IncomeN/A
Net Margins10.41%
Return on Equity20.10%
Return on Assets4.01%

Miscellaneous

EmployeesN/A
Outstanding Shares1,270,000,000

AstraZeneca (LON:AZN) Frequently Asked Questions

What is AstraZeneca's stock symbol?

AstraZeneca trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca declared a dividend on Thursday, July 27th. Investors of record on Thursday, August 10th will be paid a dividend of GBX 68.90 per share on Monday, September 11th. This represents a dividend yield of 1.35%. The ex-dividend date of this dividend is Thursday, August 10th. The official announcement can be viewed at this link. View AstraZeneca's Dividend History.

Where is AstraZeneca's stock going? Where will AstraZeneca's stock price be in 2018?

21 brokers have issued 12-month price targets for AstraZeneca's shares. Their forecasts range from GBX 3,800 to GBX 6,300. On average, they anticipate AstraZeneca's share price to reach GBX 5,296.40 in the next year. View Analyst Ratings for AstraZeneca.

Who are some of AstraZeneca's key competitors?

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the folowing people:

  • Pascal Soriot, Executive Director and Chief Executive Officer (Age 57)
  • Marc Dunoyer, Executive Director, Chief Financial Officer (Age 64)
  • Fiona Cicconi, Executive Vice-President, Human Resources
  • Sean Bohen M.D., Ph.D., Chief Medical Officer, Executive Vice President - Global Medicines Development
  • Pam P. Cheng, Executive Vice President - Operations and Information Technology (Age 45)
  • Ruud Dobber, Executive Vice President, North America
  • Bahija Jallal Ph.D., Executive Vice President, MedImmune
  • Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
  • Menelas Pangalos, Executive Vice President - IMED Biotech Unit and Global Business Development
  • Leon Wang, Executive Vice President - Asia Pacific

How do I buy AstraZeneca stock?

Shares of AstraZeneca and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is AstraZeneca's stock price today?

One share of AstraZeneca stock can currently be purchased for approximately GBX 5,043.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of £63.86 billion.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The biopharmaceutical company can be reached via phone at +44-20-73045000.


MarketBeat Community Rating for AstraZeneca (AZN)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  970 (Vote Outperform)
Underperform Votes:  1,307 (Vote Underperform)
Total Votes:  2,277
MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AstraZeneca (LON:AZN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyHold
Consensus Rating Score: 2.482.432.502.37
Ratings Breakdown: 3 Sell Rating(s)
5 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 5,296.40GBX 5,241.40GBX 5,254.90GBX 5,299.22

AstraZeneca (LON:AZN) Consensus Price Target History

Price Target History for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
1/19/2018Shore CapitalReiterated RatingHoldView Rating Details
1/18/2018JPMorgan Chase & Co.Reiterated RatingOverweightGBX 5,500View Rating Details
1/18/2018Liberum CapitalReiterated RatingHoldGBX 5,000View Rating Details
1/16/2018Jefferies GroupReiterated RatingHoldGBX 5,500View Rating Details
1/16/2018BNP ParibasReiterated RatingOutperformGBX 5,800View Rating Details
1/11/2018Deutsche BankReiterated RatingBuyGBX 5,700View Rating Details
1/10/2018CitigroupReiterated RatingBuyGBX 6,000View Rating Details
12/18/2017BarclaysReiterated RatingOverweightGBX 6,300View Rating Details
12/15/2017Bryan, Garnier & CoReiterated RatingBuyView Rating Details
12/1/2017Morgan StanleyReiterated RatingEqual weightGBX 5,000View Rating Details
11/16/2017HSBCBoost Price TargetReduceGBX 4,340 -> GBX 4,380View Rating Details
11/6/2017InvestecBoost Price TargetBuyGBX 4,900 -> GBX 5,500View Rating Details
11/10/2017S&P GlobalSet Price TargetNeutralGBX 5,000View Rating Details
11/10/2017Kepler Capital MarketsReiterated RatingBuyGBX 5,250View Rating Details
11/2/2017Goldman Sachs GroupSet Price TargetSellGBX 3,800View Rating Details
11/1/2017Berenberg BankReiterated RatingBuyGBX 5,800View Rating Details
10/16/2017Credit Suisse GroupUpgradeNeutral -> OutperformGBX 4,800 -> GBX 5,800View Rating Details
9/25/2017Sanford C. BernsteinSet Price TargetBuyGBX 5,780View Rating Details
9/21/2017Societe GeneraleReiterated RatingBuyView Rating Details
9/6/2017NatixisUpgradeNeutral -> BuyGBX 5,000 -> GBX 5,738View Rating Details
7/28/2017Beaufort SecuritiesDowngradeSellGBX 3,900View Rating Details
6/24/2016Independent ResearchSet Price TargetSellGBX 3,650View Rating Details
5/10/2016Oddo SecuritiesReiterated RatingBuyGBX 5,400View Rating Details
5/5/2016Charles StanleyUpgradeStrong-BuyView Rating Details
3/23/2016NomuraLower Price TargetHoldGBX 4,880 -> GBX 4,350View Rating Details
2/12/2016Baader BankReiterated RatingHoldGBX 4,400View Rating Details
2/9/2016AlphaValueUpgradeBuyGBX 4,640View Rating Details
2/4/2016S&P Equity ResearchSet Price TargetNeutralGBX 4,500View Rating Details
2/2/2016HandelsbankenReiterated RatingAccumulateGBX 5,220.30View Rating Details
1/28/2016Pareto SecuritiesReiterated RatingSellGBX 3,855.35View Rating Details
1/27/2016SwedbankReiterated RatingBuyGBX 5,115.47View Rating Details
(Data available from 1/21/2016 forward)

Earnings

Earnings History for AstraZeneca (LON:AZN)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

AstraZeneca (LON:AZN) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

AstraZeneca (LON:AZN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/27/2017GBX 68.901.35%8/10/20178/10/20179/11/2017
2/2/2017GBX 150.203.52%2/16/20172/16/20173/20/2017
7/28/2016GBX 68.701.37%8/11/20168/11/20169/12/2016
2/4/2016GBX 1313.16%2/18/20162/18/20163/21/2016
7/30/2015GBX 57.501.33%8/13/20158/13/20159/14/2015
(Data available from 1/1/2013 forward)

Insider Trades

AstraZeneca (LON AZN) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for AstraZeneca (LON:AZN)

AstraZeneca (LON AZN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/27/2017Nazneen RahmanInsiderBuy39GBX 4,370£1,704.30
10/27/2015Courtois,Jean-PhilippeInsiderBuy900GBX 4,423£39,807
8/28/2015Soriot,PascalInsiderBuy76,300GBX 3,960£3,021,480
5/7/2015Marc DunoyerInsiderBuy10,000GBX 4,397£439,700
4/30/2015Ann CairnsInsiderBuy1,100GBX 4,455£49,005
4/29/2015Shriti VaderaInsiderBuy3,500GBX 4,563£159,705
4/28/2015Graham ChipchaseInsiderBuy1,100GBX 4,606£50,666
4/27/2015Bruce BurlingtonInsiderBuy600GBX 4,662£27,972
(Data available from 1/1/2013 forward)

Headlines

AstraZeneca (LON AZN) News Headlines

Source:
DateHeadline
Top Picks For Pharma And Biotech Dividend RockstarsTop Picks For Pharma And Biotech Dividend Rockstars
finance.yahoo.com - January 20 at 6:45 AM
AstraZeneca says 2 new drugs get approval in JapanAstraZeneca says 2 new drugs get approval in Japan
www.marketwatch.com - January 19 at 8:31 AM
At AstraZeneca, fewer drug projects bring big productivity jumpAt AstraZeneca, fewer drug projects bring big productivity jump
finance.yahoo.com - January 19 at 8:31 AM
AstraZeneca (AZN) Given a GBX 5,500 Price Target by JPMorgan Chase & Co. AnalystsAstraZeneca (AZN) Given a GBX 5,500 Price Target by JPMorgan Chase & Co. Analysts
www.americanbankingnews.com - January 18 at 8:36 AM
Foreign Stock Roundup: Infosys Beats; AstraZenecas Asthma Drug Gets Approval in EU - NasdaqForeign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EU - Nasdaq
www.nasdaq.com - January 15 at 3:21 PM
AstraZenecas Lynparza Label Now Includes Breast Cancer - NasdaqAstraZeneca's Lynparza Label Now Includes Breast Cancer - Nasdaq
www.nasdaq.com - January 15 at 3:21 PM
AstraZeneca (AZN) Receives Neutral Rating from UBS GroupAstraZeneca (AZN) Receives Neutral Rating from UBS Group
www.americanbankingnews.com - January 15 at 10:36 AM
AstraZeneca Says FDA Oks Lynparza For Metastatic Breast Cancer - NasdaqAstraZeneca Says FDA Oks Lynparza For Metastatic Breast Cancer - Nasdaq
www.nasdaq.com - January 14 at 7:13 AM
AstraZeneca asthma treatment approved in EU - MarketWatchAstraZeneca asthma treatment approved in EU - MarketWatch
www.marketwatch.com - January 12 at 7:02 AM
AstraZenecas Asthma Drug Benralizumab Gets Approval in EU ... - NasdaqAstraZeneca's Asthma Drug Benralizumab Gets Approval in EU ... - Nasdaq
www.nasdaq.com - January 12 at 7:02 AM
AstraZeneca plc (AZN) Given Average Rating of "Hold" by BrokeragesAstraZeneca plc (AZN) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 12 at 5:42 AM
AstraZenecas Fasenra OKd in Europe - Seeking AlphaAstraZeneca's Fasenra OK'd in Europe - Seeking Alpha
seekingalpha.com - January 11 at 6:53 AM
AstraZenecas (AZN) "Buy" Rating Reiterated at Deutsche BankAstraZeneca's (AZN) "Buy" Rating Reiterated at Deutsche Bank
www.americanbankingnews.com - January 11 at 6:46 AM
AstraZeneca asthma treatment approved in EUAstraZeneca asthma treatment approved in EU
www.marketwatch.com - January 10 at 3:22 PM
AstraZeneca (AZN) Given Buy Rating at CitigroupAstraZeneca (AZN) Given Buy Rating at Citigroup
www.americanbankingnews.com - January 10 at 12:50 PM
New drug approvals hit 21-year high in 2017New drug approvals hit 21-year high in 2017
finance.yahoo.com - January 2 at 7:20 AM
These 2 European Pharmas Grabbed Upgrades Ahead Of 2018 NewsThese 2 European Pharmas Grabbed Upgrades Ahead Of 2018 News
finance.yahoo.com - December 29 at 3:20 PM
AstraZeneca (AZN) Given a GBX 5,500 Price Target at JPMorgan Chase & Co.AstraZeneca (AZN) Given a GBX 5,500 Price Target at JPMorgan Chase & Co.
www.americanbankingnews.com - December 29 at 2:12 PM
Pre-Market Most Active for Dec 29, 2017 : AZN, GCAP, BAC, TVIX, GE, QQQ, CHK, NOK, NVFY, AAPL, XIV, GOLD - NasdaqPre-Market Most Active for Dec 29, 2017 : AZN, GCAP, BAC, TVIX, GE, QQQ, CHK, NOK, NVFY, AAPL, XIV, GOLD - Nasdaq
www.nasdaq.com - December 29 at 8:51 AM
AstraZeneca Plc breached its 50 day moving average in a Bullish Manner : AZN-GB : December 29, 2017AstraZeneca Plc breached its 50 day moving average in a Bullish Manner : AZN-GB : December 29, 2017
finance.yahoo.com - December 29 at 8:51 AM
AstraZeneca (AZN) Earns "Hold" Rating from Shore CapitalAstraZeneca (AZN) Earns "Hold" Rating from Shore Capital
www.americanbankingnews.com - December 26 at 12:28 AM
What Investors Should Know About AstraZeneca PLCs (LON:AZN) Financial Strength - Yahoo FinanceWhat Investors Should Know About AstraZeneca PLC's (LON:AZN) Financial Strength - Yahoo Finance
finance.yahoo.com - December 25 at 3:55 PM
How AstraZeneca’s Other Products Portfolio Performed in 3Q17How AstraZeneca’s Other Products Portfolio Performed in 3Q17
finance.yahoo.com - December 25 at 3:55 PM
What Analysts Predict for AstraZenecaWhat Analysts Predict for AstraZeneca
finance.yahoo.com - December 25 at 3:55 PM
What Investors Should Know About AstraZeneca PLC’s (LON:AZN) Financial StrengthWhat Investors Should Know About AstraZeneca PLC’s (LON:AZN) Financial Strength
finance.yahoo.com - December 25 at 3:55 PM
What Analysts Recommend for AstraZeneca in December 2017What Analysts Recommend for AstraZeneca in December 2017
finance.yahoo.com - December 25 at 3:55 PM
AstraZeneca (AZN) Receives Buy Rating from Deutsche BankAstraZeneca (AZN) Receives Buy Rating from Deutsche Bank
www.americanbankingnews.com - December 25 at 10:46 AM
AstraZeneca (AZN) Stock Rating Reaffirmed by BarclaysAstraZeneca (AZN) Stock Rating Reaffirmed by Barclays
www.americanbankingnews.com - December 24 at 7:10 PM
AstraZeneca (AZN) Announces FDA Updated SYMBICORT Label with LABA Safety Class Revisions and Removed ... - StreetInsider.comAstraZeneca (AZN) Announces FDA Updated SYMBICORT Label with LABA Safety Class Revisions and Removed ... - StreetInsider.com
www.streetinsider.com - December 21 at 3:21 PM
Pharma And Biotech Dividend Stocks Of The Month: Hikma Pharmaceuticals And MorePharma And Biotech Dividend Stocks Of The Month: Hikma Pharmaceuticals And More
finance.yahoo.com - December 20 at 6:54 AM
AstraZeneca: FDA accepts Tagrisso review - MarketWatchAstraZeneca: FDA accepts Tagrisso review - MarketWatch
www.marketwatch.com - December 19 at 7:22 AM
Over 20 percent of UK companies faced shareholder revolt - pay studyOver 20 percent of UK companies faced shareholder revolt - pay study
finance.yahoo.com - December 19 at 7:22 AM
ETFs with exposure to AstraZeneca Plc : December 18, 2017ETFs with exposure to AstraZeneca Plc : December 18, 2017
finance.yahoo.com - December 18 at 3:21 PM
AstraZeneca: FDA Accepts SNDA For Tagrisso, Grants Priority ... - NasdaqAstraZeneca: FDA Accepts SNDA For Tagrisso, Grants Priority ... - Nasdaq
www.nasdaq.com - December 18 at 6:55 AM
AstraZeneca PLC (AZN) Receives Consensus Recommendation of "Hold" from AnalystsAstraZeneca PLC (AZN) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 18 at 5:40 AM
AstraZeneca (AZN) Earns "Buy" Rating from CitigroupAstraZeneca (AZN) Earns "Buy" Rating from Citigroup
www.americanbankingnews.com - December 17 at 12:50 PM
AstraZeneca (AZN) Rating Reiterated by Bryan, Garnier & CoAstraZeneca (AZN) Rating Reiterated by Bryan, Garnier & Co
www.americanbankingnews.com - December 15 at 11:28 PM
AstraZeneca (AZN) Investor Science Late-Stage Conference Call (Transcript) - Seeking AlphaAstraZeneca (AZN) Investor Science Late-Stage Conference Call (Transcript) - Seeking Alpha
seekingalpha.com - December 15 at 6:47 AM
Merck raises stakes in lung cancer as rivals close inMerck raises stakes in lung cancer as rivals close in
finance.yahoo.com - December 11 at 6:48 AM
AstraZeneca (AZN) Price Target Increased to GBX 5,700 by Analysts at Deutsche BankAstraZeneca (AZN) Price Target Increased to GBX 5,700 by Analysts at Deutsche Bank
www.americanbankingnews.com - December 10 at 11:34 PM
ETFs with exposure to AstraZeneca Plc : December 7, 2017ETFs with exposure to AstraZeneca Plc : December 7, 2017
finance.yahoo.com - December 7 at 3:22 PM
[$$] AstraZeneca Sells $10.7 Million in Albireo Stock[$$] AstraZeneca Sells $10.7 Million in Albireo Stock
finance.yahoo.com - December 6 at 7:30 AM
AstraZeneca Plc :AZN-GB: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017AstraZeneca Plc :AZN-GB: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017
finance.yahoo.com - December 6 at 7:30 AM
A Deadly Drug Cocktail Shines a Light on an AstraZeneca BlockbusterA Deadly Drug Cocktail Shines a Light on an AstraZeneca Blockbuster
finance.yahoo.com - December 6 at 7:30 AM
GSK, other drugmakers bet on post-Brexit UK scienceGSK, other drugmakers bet on post-Brexit UK science
finance.yahoo.com - December 6 at 7:30 AM
[$$] AstraZeneca Sells $6.6M in G1 Therapeutics Stock[$$] AstraZeneca Sells $6.6M in G1 Therapeutics Stock
finance.yahoo.com - December 5 at 3:21 PM
Notable Two Hundred Day Moving Average Cross - AZN - NasdaqNotable Two Hundred Day Moving Average Cross - AZN - Nasdaq
www.nasdaq.com - December 5 at 7:09 AM
AstraZeneca is Now Oversold (AZN) - NasdaqAstraZeneca is Now Oversold (AZN) - Nasdaq
www.nasdaq.com - December 5 at 7:09 AM
AstraZenecas (AZN) Solid Earnings Visibility Keep it a Buy - Investorplace.comAstraZeneca's (AZN) Solid Earnings Visibility Keep it a Buy - Investorplace.com
www.investorplace.com - December 1 at 3:22 PM
AstraZeneca’s (AZN) Solid Earnings Visibility Keep it a BuyAstraZeneca’s (AZN) Solid Earnings Visibility Keep it a Buy
investorplace.com - December 1 at 12:48 PM

SEC Filings

AstraZeneca (LON:AZN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

AstraZeneca (LON AZN) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.